Dr. Zengjun Xu worked in CDER, for FDA for 11 years, and participated in the review and approval of multiple IND applications at the Office of New Drugs (OND) as a major reviewer. After leaving FDA, he worked with CDE, NMPA in China from June 2017 to June 2020 as the chief scientist participating in the reform of national drug review and approval processes.
Dr. Thomas G. Evans was an associate professor at the University of Rochester, professor at UC Davis School of Medicine and director of the Division of Infectious Diseases, where he led a number of NIH and clinical studies as the PI. With 20 years of core management experience in the biomedical industry, Dr. Evans served as CEO/CSO/CMO for several biotech companies and as the global Vice-President of drug discovery and translational medicine in infectious diseases at Novartis. He was responsible for more than a hundred R&D projects from drug discovery to late phase development.
Dr. Zheng Yin was the Managing Director of SDIC Fund, Ltd., responsible for equity investment in the medicine and health sector, including investment for CanSinoBio, Ascentage Pharma, BrightGene, Dizal, Raybow and EpimAb, etc. Dr. Yin served as the Dean of the College of Pharmacy at Nankai University, Deputy Director at the State Key Laboratory of Medicinal Chemical Biology, and Executive Director at the Center of Basic Molecular Science, Department of Chemistry, Tsinghua University.
Dr. Duanyun Si conducted his post-doctoral researches in drug metabolism, pharmacokinetics and other areas in France and the United States. With 36 years of work experience in teaching, scientific research and management, Dr. Si has so far helped various new drug developers successfully obtain IND approval for clinical trials and licensing from NMPA for nearly 100 innovative drugs and pharmaceutical agents.
Dr. Hu pursued his post-doctoral research at MIT, and worked on the R&D of innovative drugs for years for Roche, GSK, Merck, Johnson and other well-known international pharmaceutical companies. Dr. Hu participated in or led the pharmaceutical studies of many small molecules and biological products from preclinical research to commercialization. Furthermore, he accumulated extensive experience in full life cycle development of innovative drugs and development and application of new pharmaceutical technologies.
Professor Kai Gao served as a Deputy Director at the Office of Recombinant Drugs at National Institutes for Food and Drug Control of NMPA, was the Director at the Office of Monoclonal Antibody, and a reviewer for the Department of Biomedicine in CDE. Mr. Gao was also recruited as a scientist and technology officer by the Division of Technical Standards and Laws, Department of Essential Medicines, World Health Organization (WHO) to participate in setting standards for the manufacture and quality control of vaccines and biologics for WHO.
